Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2768Triple Negative Breast Neoplasms 406Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 49Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28Sarcoma 27HER2-positive Breast Cancer 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

pyrotinib 1Drug Therapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Metastatic Breast Cancer × Breast × Clear all
NCT03691051 2023-09-25

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

Henan Cancer Hospital

Phase 2 Unknown
78 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

NCT04681287 2023-09-25

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

Henan Cancer Hospital

Phase 2 Unknown
46 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡